Prometheus up­sizes IPO by 33% ahead of pric­ing; Hu­mani­gen se­cures loan of up to $80M to de­vel­op lenzilum­ab

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter ini­tial­ly pen­cil­ing in a $125 mil­lion IPO, Prometheus is up­siz­ing that goal a cou­ple dozen mil­lion high­er.

The San Diego-based biotech is now es­ti­mat­ing a $167 mil­lion raise from their ex­pect­ed jump to Nas­daq, ac­cord­ing to Re­nais­sance Cap­i­tal, a 33% in­crease from when they first filed their S-1. Prometheus had set its terms ear­li­er this week, but now plans to of­fer 9 mil­lion shares in­stead of 7.4 mil­lion in the $18 to $19 range.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER